SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Matritech (NASDAQ - NMPS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: angra manyu who wrote ()9/19/1999 1:52:00 PM
From: burner   of 849
 
If you are interested in protein based BC research:

BioLabs' Joint Venture Partner Receives Approval to Proceed With FDA Clinical Trials


NEW YORK, April 28 /PRNewswire/ -- BioLabs, Inc.
(OTC Bulletin Board: BILB), is pleased to announce that Biotherapies
Incorporated has received approval from the FDA to commence its Phase I and II
clinical trials utilizing mammastatin as a therapy to treat breast cancer.
The trials will start in May, 1999 and will be conducted at the University
of Texas M.D. Anderson Cancer Center. The scope of the trial will include
safety testing and dose optimization studies of human mammary epithelial cell
derived mammastatin (native mammastatin) for use as a replacement therapy in
refractory Stage IV breast cancer patients.
Preliminary laboratory research on over 1,000 blood and breast tissue
samples has consistently shown that mammastatin is a key protein for
controlling abnormal cell growth in breast tissue samples. In addition,
research on 29 late stage breast cancer patients has demonstrated that
mammastatin replacement therapy has been over 70% effective in preventing
breast cancer growth.
In addition to BioLabs' equity interest in Biotherapies, BioLabs holds a
50% interest in a joint venture to manufacture and distribute the Mammastatin
Serum Assay (MSA) blood test. It is anticipated that the MSA test will
potentially screen for breast cancer risk by measuring the mammastatin levels
in women's blood. Preliminary research has demonstrated that mammastatin is
present in the blood of healthy women and either reduced or absent in
approximately 90% of breast cancer patients. The joint venture agreement
includes exclusive worldwide rights to manufacture, market and distribute the
MSA test. Trials under a 510K application are anticipated to commence in
June, 1999 and will likely be completed in early 2000.
Investor information can be found on the web at: biolabs.com or
marketmanagement.com . Information about mammastatin can be found on the
Biotherapies website at: biotherapiesinc.com .
Press and investors can request information packages by calling Capital
Media Group at: (800) 437-3551.
"Safe Harbor" Statement Under The Private Securities Litigation Reform Act
of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are forward-looking statements, within the meaning
of the Private Securities Litigation Reform Act of 1995. The results
anticipated by any or all of these forward-looking statements may not occur.

SOURCE BioLabs, Inc.
Web Site: biotherapiesinc.com
Web Site: biolabs.com
Web site: vsbio.vwh.net
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News